PDS Planning Inc Buys 2,155 Shares of Johnson & Johnson (NYSE:JNJ)

PDS Planning Inc lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 14.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 16,997 shares of the company’s stock after purchasing an additional 2,155 shares during the quarter. PDS Planning Inc’s holdings in Johnson & Johnson were worth $2,458,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swedbank AB increased its stake in Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after acquiring an additional 111,570 shares during the last quarter. Principal Financial Group Inc. increased its stake in Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after acquiring an additional 329,473 shares during the last quarter. United Bank increased its stake in Johnson & Johnson by 5.6% in the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after acquiring an additional 202 shares during the last quarter. Clarkston Capital Partners LLC increased its stake in Johnson & Johnson by 1.3% in the 3rd quarter. Clarkston Capital Partners LLC now owns 123,157 shares of the company’s stock worth $19,959,000 after acquiring an additional 1,632 shares during the last quarter. Finally, TrinityPoint Wealth LLC increased its stake in Johnson & Johnson by 0.6% in the 3rd quarter. TrinityPoint Wealth LLC now owns 46,994 shares of the company’s stock worth $7,616,000 after acquiring an additional 295 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 0.1 %

NYSE JNJ opened at $162.94 on Tuesday. The stock has a market cap of $392.66 billion, a P/E ratio of 24.50, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a 50 day simple moving average of $155.37 and a two-hundred day simple moving average of $156.26. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 74.59%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Wells Fargo & Company decreased their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.